[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100648434":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":27,"centralContacts":28,"locations":27,"responsibleParty":34,"collaborators":27,"id":36,"slug":37,"hasResults":38,"nctId":39,"briefTitle":40,"officialTitle":41,"acronym":42,"eligibilityCriteria":43,"healthyVolunteers":44,"sex":45,"minAge":46,"maxAge":27,"enrollmentInfo":47,"targetDuration":27,"studyType":50,"phases":51,"briefSummary":53,"conditions":54,"keywords":27,"overallStatus":56,"whyStopped":27,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":27},{"fullName":5,"class":6},"Assistance Publique - Hôpitaux de Paris","OTHER",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Patients with septic shock","ACTIVE_COMPARATOR","Blood samples will be collected at 6, 24, and 72 hours after study inclusion",[13],"Other: Collection of fluid samples",{"label":15,"type":10,"description":16,"interventionNames":17},"critically ill control patients","Critically ill control patients, including patients with sepsis without circulatory failure and patients with cardiogenic shock, will undergo blood sampling at 6, 24, and 72 hours.",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"healthy volunteer","blood sampling at inclusion",[13],[23],{"type":6,"name":24,"description":25,"armGroupLabels":26,"otherNames":27},"Collection of fluid samples","blood sample and urinary",[9,15,19],null,[29],{"name":30,"role":31,"phone":32,"phoneExt":27,"email":33},"Adrien PICOD, PhD","CONTACT","+33 1 48 95 55 55","adrien.picod@aphp.fr",{"type":35,"investigatorFullName":27,"investigatorTitle":27,"investigatorAffiliation":27,"oldNameTitle":27,"oldOrganization":27},"SPONSOR","100648434","alterations-of-the-renin-angiotensin-aldosterone-system-in-septic-shock-100648434",false,"NCT07721974","Alterations of the Renin-angiotensin-aldosterone System in sEptic Shock","\" Étude Des altérations du système rénine-angiotensine-aldostérone au Cours du Choc Septique \" Alterations of the Renin-angiotensin-aldosterone System in sEptic Shock","ARES","Inclusion Criteria:\n\nAdult patients with septic shock:\n\n* Proven or suspected infection.\n* Persistent arterial hypotension requiring norepinephrine administration to maintain a mean arterial pressure above 65 mmHg despite adequate fluid resuscitation.\n* Hyperlactatemia \\> 2 mmol\u002FL.\n\nAdult critically ill control patients with sepsis without circulatory failure:\n\n* Proven or suspected infection.\n* Absence of persistent arterial hypotension requiring norepinephrine administration to maintain a mean arterial pressure above 65 mmHg.\n* An increase of at least 2 points in the SOFA score attributable to infection.\n\nAdult critically ill control patients with cardiogenic shock:\n\n* Acute cardiac disease, such as myocardial infarction.\n* Persistent arterial hypotension requiring norepinephrine administration to maintain a mean arterial pressure above 65 mmHg despite adequate fluid resuscitation.\n* Low cardiac output: cardiac index \\\u003C 2.2 L\u002Fmin\u002Fm² or the need for inotropic support (including norepinephrine) to maintain a cardiac index \\> 2.2 L\u002Fmin\u002Fm².\n* Elevated left ventricular filling pressures, measured invasively or estimated by echocardiography.\n* Hyperlactatemia \\> 2 mmol\u002FL.\n\nAdult healthy volunteers:\n\n* Absence of active or chronic disease.\n* Absence of long-term medication use.\n* No surgery or medication intake within the previous month.\n* Absence of ongoing pregnancy.\n* Non-smoker.\n\nExclusion Criteria:\n\n* Patients deprived of liberty by judicial or administrative decision.\n* Patients admitted to the intensive care unit for more than 48 hours.\n* Patients previously enrolled in an interventional study with overlapping follow-up.\n* Patients benefiting from State Medical Aid (AME).",true,"ALL","18 Years",{"count":48,"type":49},320,"ESTIMATED","INTERVENTIONAL",[52],"NA","Septic shock is a common and life-threatening condition associated with an in-hospital mortality rate exceeding 40%. The symptomatic management of septic shock relies primarily on vasopressor therapy, particularly norepinephrine. However, the use of high doses of norepinephrine may lead to adverse effects, prompting the search for alternative therapeutic strategies, including angiotensin II, which has recently been investigated as an adjunctive vasopressor.\n\nIndeed, alterations of the renin-angiotensin-aldosterone system (RAAS), particularly a relative deficiency of angiotensin II, have been hypothesized to occur during septic shock. However, to date, no human study has used gold-standard techniques for measuring RAAS peptides to confirm this hypothesis.\n\nFurthermore, it remains unclear whether these alterations are specific to septic shock or may also be observed in less severe infections (sepsis) or in other forms of circulatory failure, such as cardiogenic shock.",[55],"Septic Shock","NOT_YET_RECRUITING","2026-07-20",{"date":59,"type":60},"2026-07-23","ACTUAL",{"date":62,"type":49},"2026-09-15",{"date":64,"type":49},"2031-10",{"name":5,"class":6}]